A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19

RATIONALE: There are limited therapeutic options for patients with coronavirus disease (COVID-19)-related acute respiratory distress syndrome with inflammation-mediated lung injury. Mesenchymal stromal cells offer promise as immunomodulatory agents. OBJECTIVES: Evaluation of efficacy and safety of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowdish, Michael E., Barkauskas, Christina E., Overbey, Jessica R., Gottlieb, Robert L., Osman, Keren, Duggal, Abhijit, Marks, Mary E., Hupf, Jonathan, Fernandes, Eustace, Leshnower, Bradley G., Golob, Jonathan L., Iribarne, Alexander, Rassias, Athos J., Moquete, Ellen G., O’Sullivan, Karen, Chang, Helena L., Williams, Judson B., Parnia, Sam, Patel, Nirav C., Desai, Nimesh D., Vekstein, Andrew M., Hollister, Beth A., Possemato, Tammie, Romero, Christian, Hou, Peter C., Burke, Elizabeth, Hayes, Jack, Grossman, Fred, Itescu, Silviu, Gillinov, Marc, Pagani, Francis D., O’Gara, Patrick T., Mack, Michael J., Smith, Peter K., Bagiella, Emilia, Moskowitz, Alan J., Gelijns, Annetine C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896641/
https://www.ncbi.nlm.nih.gov/pubmed/36099435
http://dx.doi.org/10.1164/rccm.202201-0157OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896641/
https://www.ncbi.nlm.nih.gov/pubmed/36099435
http://dx.doi.org/10.1164/rccm.202201-0157OC

Ejemplares similares